Large genetic study uncovers new Alzheimer’s drug targets

1. juni 2026

Rapporteret af AI

A major analysis of genetic data has linked 127 gene locations to Alzheimer’s disease, including 48 previously unidentified ones. Researchers also flagged several genes as promising drug targets and highlighted changes in immune and nerve cells.

The study examined genome information from nearly 110,000 people diagnosed with Alzheimer’s and 74,000 others who had a parent with the condition. It compared these against data from 2.6 million people without the disease. This effort identified 127 associated gene locations, 48 of which are new findings.

Relaterede artikler

Illustration of mutated blood cells entering the brain through the blood-brain barrier, linked to Alzheimer's pathology.

Study finds blood-cancer-linked mutations in brain immune cells tied to Alzheimer’s pathology

12. juni 2026 Rapporteret af AI Billede genereret af AI Faktatjekket

Researchers at Boston Children’s Hospital report that mutations commonly associated with clonal blood-cell expansion and some blood cancers were enriched in microglia-like immune cells in Alzheimer’s brains and were also detectable in matched blood samples. The Cell study proposes that age- or injury-related weakening of the blood-brain barrier could allow mutated blood immune cells to enter the brain, potentially amplifying inflammation and contributing to neurodegeneration.

Japan scientists identify clusters of protein believed to trigger Alzheimer’s disease

Japanese researchers have identified a new seed of the amyloid beta protein. The discovery could lead to early-stage therapy for the neurodegenerative disease.

USC researchers identify compounds targeting Alzheimer’s brain inflammation

26. maj 2026 Rapporteret af AI

Scientists at the University of Southern California have found experimental compounds that may reduce harmful brain inflammation associated with Alzheimer’s disease. The work focuses on the enzyme cPLA2 and people who carry the high-risk APOE4 gene.

Sundhed

UC Riverside study proposes new Alzheimer's trigger

Sundhed

Scientists restore memory in Alzheimer's mice by blocking PTP1B

Sundhed

Study finds alzheimer's risk factors hit women harder

Cochrane review questions benefits of anti-amyloid Alzheimer’s drugs

A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.

Sundhedsundersøgelse for Alzheimers tilbydes raske – læger advarer

5. juli 2026 Rapporteret af AI

En ny blodprøve kan afsløre risiko for Alzheimers op til 20 år før symptomerne opstår. Private klinikker tilbyder testen til raske personer, hvilket møder kritik fra læger.

søndag d. 26. juli 2026, 11.21

Large genetic study uncovers new Alzheimer’s drug targets

Relaterede artikler

Study finds blood-cancer-linked mutations in brain immune cells tied to Alzheimer’s pathology

Japan scientists identify clusters of protein believed to trigger Alzheimer’s disease

USC researchers identify compounds targeting Alzheimer’s brain inflammation

UC Riverside study proposes new Alzheimer's trigger

Scientists restore memory in Alzheimer's mice by blocking PTP1B

Study finds alzheimer's risk factors hit women harder

Cochrane review questions benefits of anti-amyloid Alzheimer’s drugs

Sundhedsundersøgelse for Alzheimers tilbydes raske – læger advarer

Study pinpoints microglial shift in Alzheimer's progression

Study finds SuperAgers’ exceptional memory is not explained by common Alzheimer’s risk genes

Study links APOE2 variant to stronger DNA repair and reduced cellular aging in human neurons

Blodprøve kan afsløre tegn på Alzheimers år i forvejen

Indiana university team targets idol enzyme to treat alzheimer's

Dette websted bruger cookies